Interleukin 6, Interleukin 1 beta, Tumor necrosis factor alpha (IL-6, IL-1β, TNF-α)

Interleukin-6, interleukin-1 beta, and tumor necrosis factor alpha are the principal pro-inflammatory cytokines secreted by immune cells such as monocytes, macrophages, and T lymphocytes in response to infections, tissue injury, or cellular stress. They act through individual receptors to orchestrate inflammation, regulate the acute-phase response, promote fever, mediate leukocyte recruitment and activation, and influence cell death and proliferation. Dysregulated activity of these cytokines is central to the pathogenesis of many chronic inflammatory and autoimmune diseases, making them major therapeutic targets in conditions such as rheumatoid arthritis, osteoarthritis, and others. Specific inhibitors are approved and used clinically to block their activity and ameliorate disease symptoms. However, targeting these cytokines can impair host defense and carries notable safety risks. Grouping “IL6/IL1β/TNFα” as a single target is not accurate for structured data purposes: each cytokine should be considered a distinct molecular entity, with separate roles, regulators, pathways, and therapeutic implications.

Other names

Interleukin-6IL6Interleukin-1 betaIL1BTumor necrosis factor alphaTNFATNFTNF-α

Neutralization of cytokine activity by antibody binding; Blockade of receptor-ligand interaction; Inhibition of downstream signaling pathways (e.g., JAK/STAT for IL-6, NF-κB for TNF-α/IL-1β)